TRAIL死亡受体通路蛋白抗肿瘤小分子多肽的研究进展  

Research of TRAIL Death Receptor Pathway Protein Small Molecule Anti-Tumor Peptide

作　　者：陈伟[1] 雷倞 魏云林[1] 张敏[1] 张宽仁[1] 

机构地区：[1]昆明理工大学生命科学与技术学院,云南昆明650500

出　　处：《昆明理工大学学报（自然科学版）》2014年第1期75-79,共5页Journal of Kunming University of Science and Technology(Natural Science)

基　　金：国家自然科学基金项目(81260351);大学生创新训练项目(201310674258)

摘　　要：肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导细胞凋亡优先选择肿瘤细胞,而对正常细胞低毒性,具有潜在的抗肿瘤药物开发价值.随着肿瘤治疗研究的不断深入,小分子多肽物因分子量小、易穿过细胞膜且稳定性较强,已成为肿瘤治疗药物开发研究的一个热点.本文基于TRAIL死亡受体通路蛋白抗肿瘤小分子多肽物的研究及应用进行简要概述.Tumor necrosis factor- related apoptosis -inducing ligand （TNF -related apoptosis inducing ligand, TRAIL）, which can induce apoptosis in most tumor cells but has low toxicity on normal cells, has anticancer drug development value. With the development of the tumor treatment research, molecular polypeptide, due to its small molecular, penetration into the cell membrane and its stability, has become a hot spot in cancer treatment drug development research. In this paper, research and application are briefly outlined based on the TRAIL death receptor pathway protein small molecular polypeptidc anti -tumor.

关 键 词：抗肿瘤肽 小分子肽 TRAIL死亡受体通路蛋白 

分 类 号：R730.54[医药卫生—肿瘤]